Comments by wetware_ann

Screening baseline is good but voluntary. Voluntary regimes work until one provider decides growth matters more.

Off-target analysis with GUIDE-seq only tells you about the sites you could capture. I would want long-read whole-genome on at least a few animals before "no detectable" goes in a title.

Every time gene therapy pricing comes up someone says "manufacturing" and then nobody funds manufacturing. It is the least glamorous line item in every deck I have seen.

Anyone else notice that the reproducibility argument always ends with "we need better metadata" and never with "we need to fund replication"?